The Invitae Hyperphenylalaninemia Panel analyzes 6 genes that are known to cause increased plasma phenylalanine levels. Hyperphenylalaninemia is most commonly due to impaired function of phenylalanine hydroxylase (PAH), the enzyme that catabolizes the amino acid phenylalanine to tyrosine, but it can also be due to defects in the regeneration or biosynthesis of the enzyme cofactor tetrahydrobiopterin (BH4).
Any individual with a positive newborn screen for phenylketonuria (PKU), elevated plasma phenylalanine, abnormal urine pterins (tetrahydrobiopterin compounds), or a suspected diagnosis of hyperphenylalaninemia based on clinical presentation or laboratory results should be tested for hyperphenylalaninemias. Age of diagnosis and subsequent metabolic management are some of the greatest determinants of long-term outcome.
GCH1 PAH PCBD1 PTS QDPR SPR
GCH1 PAH PCBD1 PTS QDPR SPR
The hyperphenylalaninemias are a diverse group of conditions that result from the disruption of phenylalanine homeostasis. This disruption can occur due to impaired catabolism of the amino acid phenylalanine by the enzyme phenylalanine hydroxylase (PAH), causing phenylketonuria (PKU); it can also occur due to defects of the enzymatic cofactor tetrahydrobiopterin (BH4).
An affected individual is homozygous or compound heterozygous for pathogenic variants in the same gene (except for GCH1, which has autosomal recessive and dominant forms). Biallelic variants in any of the five genes can cause hyperphenylalaninemia.
|GCH1||Tetrahydrobiopterin biosynthesis||GTP cyclohydrolase deficiency (a.k.a.|
|PCBD1||Tetrahydrobiopterin recycling||Pterin-4-α-carbinolamine dehydratase deficiency|
|PTS||Tetrahydrobiopterin biosynthesis||6-pyruvoyltetrahydropterin synthase (PTS) deficiency|
|QDPR||Tetrahydrobiopterin recycling||Quinoid dihydropteridine reductase (DHPR) deficiency|
|SPR||Tetrahydrobiopterin biosynthesis||Sepiapterin reductase (SR) deficiency|
Phenylketonuria (PKU) is the most common cause of hyperphenylalaninemia and is due to a deficiency of the enzyme phenylalanine hydroxylase (PAH). This enzyme catalyzes the hydroxylation of the amino acid phenylalanine to tyrosine. Reduction in PAH activity leads to a metabolic block with the accumulation of excess phenylalanine and metabolic byproducts such as phenylketones. Additionally, there is a reduction of tyrosine (a precursor for neurotransmitter synthesis), so neurotransmitter production and other downstream pathways are also impacted.
Phenylketonuria has wide clinical heterogeneity ranging from benign hyperphenylalaninemia to severe, classic PKU. All forms present with a normal birth and neonatal period, but excess phenylalanine is neurotoxic and, if left untreated, a progressive, insidious neurocognitive impairment occurs proportionate to the phenylalanine elevation. Symptoms can include microcephaly, epilepsy, mental retardation, behavior problems, eczema, pigmentation lighter than the family constellation, decreased myelin formation, and reduced dopamine, norepinephrine, and serotonin production. Additionally, excessive phenylalanine and its metabolic byproduct, phenylketones, have been attributed to the musty/mousy odor detectable in some untreated individuals.
All forms of PAH-hyperphenylalaninemia are treatable with dietary phenylalanine restriction commensurate to the amount of residual PAH activity. Classic, severe cases tolerate <500 mg dietary phenylalanine/day; mild to moderate phenylketonurics tolerate approximately <700 mg of phenylalanine; and benign hyperphenylketonurics maintain a plasma phenylalanine level of 10 mg/dL (<600 umol/L) on an unrestricted diet (normal <2 mg/dL). Affected individuals that are detected in the newborn period and placed on a phenylalanine-restricted diet can achieve normal intelligence, though there is an increased risk for learning difficulties and emotional problems despite the most stringent metabolic control. Any dietary interventions must be managed by a metabolic nutritionist to avoid any nutritional deficiencies.
Less common hyperphenylalaninemias are due to defects in tetrahydrobiopterin (BH4) biosynthesis or recycling. BH4 serves as a cofactor for PAH, the amino acid hydroxylases tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH), nitric oxide synthase, and glyceryl-ether monooxygenase. TH and TPH are involved in biosynthesis of the neurotransmitters dopamine and serotonin, so BH4 defects alter neurotransmitter levels, which results in significant neurologic symptoms.
Pathogenic variants in GCH1, PTS and SPR result in the BH4 biosynthesis disorders GTP cyclohydrolase deficiency (aka dopa-responsive dystonia), 6-pyruvoyltetrahydropterin synthase deficiency and sepiapterin reductase (SR) deficiency.
GTP cyclohydrolase deficiency presents with an autosomal dominant and an autosomal recessive form. Approximately 90% of individuals present with the autosomal dominant form, which is typically characterized by a postural dystonia that appears around age six years (often the foot), then subsides around ten years of age, when a postural tremor appears; later, parkinsonism develops. Diurnal fluctuation of the symptoms (increase of symptoms in the evening and lessening in the morning) is characteristic of the condition. Intellectual function generally remains normal, as does autonomic function. This form is remarkably responsive to low doses of oral L-dopa supplementation. The recessive form presents with hyperphenylalaninemia within the first six months of life, significant developmental delay, truncal hypotonia, hypertonia of the extremities, tremors, seizures, and, at times, autonomic dysfunction. Treatment involves oral L-dopa replacement and BH4 supplementation.
PTS deficiency presents with severe and attenuated forms. The severe form results in a clinical presentation similar to that of autosomal dominant GCH1 deficiency and includes hyperphenylalaninemia and neurotransmitter deficiencies. The initial presentation includes abnormal movements and developmental delay in the first few months of life. The attenuated form is considered peripheral and has an excellent prognosis with treatment that includes supplemental BH4 and dietary phenylalanine restriction.
SR deficiency presents similarly to the other biopterin biosynthesis conditions with primarily neurologic features that appear in early infancy. Affected individuals can have any of the following symptoms with diurnal fluctuations: speech and motor delays, learning disabilities and mental retardation, hypotonia, weakness, dystonic posturing, spasticity, tremor, ataxia, gait disturbances, cerebral palsy, Parkinsonism, oculogyric crisis and chorea. Additionally, psychiatric features such as depressed affect, aggressiveness and hypersomnolence have also been reported. SR has proven responsive to regimens with varying combinations of L-dopa, carbidopa and 5-hydroxytryptophan. SR deficiency does not feature elevated plasma phenylalanine levels so is not detectable on newborn screening. Biochemically, it can be diagnosed through abnormalities in CSF neurotransmitter metabolites.
Pathogenic variants in PCBD1 and QDPR lead to complications of biopterin recycling. Variants in PCBD1 cause elevated levels of phenylalanine and urine pterins (though neurotransmitter levels are normal) and result in a clinically benign condition. Affected individuals are usually picked up through newborn screening and reported cases have remained asymptomatic without treatment. Pathogenic variants in QDPR often leads to severe developmental delay, brain abnormalities, and sudden death for incompletely understood reasons. Treatment involves any combination of dietary phenylalanine restriction and BH4 and neurotransmitter supplementation; the degree of responsiveness varies.
For patients with a biochemical diagnosis of hyperphenylalaninemia, at least 97% will have two pathogenic variants in PAH. The remaining <3% will have a BH4 defect.
Of the <3% with a BH4 defect:
Variants in PAH, PTS, PCBD1, QDPR and SPR are inherited in an autosomal recessive manner. GCH1 variants have autosomal recessive and dominant inheritance; 90% of cases are dominantly inherited. Females are affected more frequently by variants in GCH1 (2:1) than males (6:1). Additionally, greater penetrance of GCH1 variants has been reported in females (87%–100% penetrance) than in males (35%–55% penetrance).
The general population incidence of PAH hyperphenylalaninemia is 1 in 10,000–20,000. Incidence varies on country of origin and has been reported at 1 in 2,600 in Turkey and 1 in 143,000 in Japan. An estimated <3% of hyperphenylalaninemia cases are due to a BH4 defect.
This panel may be appropriate for any individual with:
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|